This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

This study has been terminated.
(Study was terminated due to low enrollment)
Information provided by:
AstraZeneca Identifier:
First received: April 12, 2007
Last updated: January 24, 2011
Last verified: January 2011
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Condition Intervention Phase
Lymphoma Drug: AZD4877 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Estimated Enrollment: 75
Study Start Date: March 2007
Study Completion Date: August 2007

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with AML, a certain type of ALL, NHL and MM
  • certain types of cancer of the lymph nodes
  • certain types of leukemias (blood cancers)
  • disease has or will fail with other treatments
  • relatively good overall health other than your cancer

Exclusion Criteria:

  • poor bone marrow function (not producing enough blood cells)
  • serious heart conditions
  • poor liver or kidney function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00460460

United States, New York
Research site
Buffalo, New York, United States
Research Site
New York, New York, United States
Canada, Ontario
Research Site
Toronto, Ontario, Canada
Sponsors and Collaborators
Study Director: Judith Ochs, MD AstraZeneca
  More Information Identifier: NCT00460460     History of Changes
Other Study ID Numbers: D2782C00002
Study First Received: April 12, 2007
Last Updated: January 24, 2011

Keywords provided by AstraZeneca:
Phase I
MM processed this record on July 21, 2017